Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMF Biomarker for Cyclosporine and Dupilumab in Atopic Dermatitis
NCT04878770Unknown
- Sponsor
- Erasmus MC
- Start
- Aug 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of dupilumab + topical corticosteroids and cyclosporine in atopic dermatitis (AD), sponsored by Erasmus MC. Status: unknown.
02
Drugs
dupilumab + topical corticosteroidscyclosporine
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04878770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878770.